Decreased serum level of miR-146a as sign of chronic inflammation in type 2 diabetic patients

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Baldeón, Lucy R ^a,b   Weigelt, Karin ^a   De Wit, Harm ^a   Ozcan, Behiye ^a   Van Oudenaren, Adri ^a   Sempértegui, Fernando ^b   Sijbrands, Eric ^a   Grosse, Laura ^d   Freire, Wilma ^c   Drexhage, Hemmo A ^a,b   Leenen, Pieter J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSIDAD CENTRAL DEL ECUADOR   (Ecuador)

^c UNIVERSIDAD SAN FRANCISCO DE QUITO   (Ecuador)

^d UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CARBON TETRACHLORIDE; CHEMOKINE; CYTOKINE; GLUCOSE; GROWTH FACTOR; HEMOGLOBIN A1C; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; LIPID; MICRORNA 146A; MICRORNA 155; ORAL ANTIDIABETIC AGENT; BIOLOGICAL MARKER; MICRORNA; MIRN146 MICRORNA, HUMAN; MIRN155 MICRORNA, HUMAN; SIGNAL PEPTIDE;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; CHRONIC INFLAMMATION; CONTROLLED STUDY; CYTOMETRY; DYSLIPIDEMIA; FEMALE; GLUCOSE HOMEOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SEROLOGY; VERY ELDERLY; BLOOD; CASE CONTROL STUDY; CHRONIC DISEASE; GENETICS; INFLAMMATION; PATHOLOGY;

ADULT; BIOMARKERS; CASE-CONTROL STUDIES; CHRONIC DISEASE; CYTOKINES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INFLAMMATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPIDS; MALE; MICRORNAS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84918526111     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0115209     Document Type: Article

References (53)

1. Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259(5091): 87-91.
2. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, et al. (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271(5249): 665-668.
3. Peraldi P, Hotamisligil GS, Buurman WA, White MF, Spiegelman BM (1996) Tumor necrosis factor (TNF)-alpha inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase. The Journal of biological chemistry 1996 271(22): 13018-13022.
4. Scazzocchio B, Vari R, D'Archivio M, Santangelo C, Filesi C, et al. (2009) Oxidized LDL impair adipocyte response to insulin by activating serine/threonine kinases. Journal of lipid research 50(5): 832-845.
5. Israel A (2010) The IKK complex, a central regulator of NF-kappaB activation. Cold Spring Harbor perspectives in biology 2(3): a000158.
6. Nakamori Y, Emoto M, Fukuda N, Taguchi A, Okuya S, et al. (2006) Myosin motor Myo1c and its receptor NEMO/IKK-gamma promote TNF-alpha-induced serine307 phosphorylation of IRS-1. The Journal of cell biology 173(5): 665-671.
7. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, et al. (2006) Recent advances in the relationship between obesity, inflammation, and insulin resistance. European cytokine network 17(1): 4-12.
8. Hooper PL (2009) Inflammation, heat shock proteins, and type 2 diabetes. Cell stress & chaperones 14(2): 113-115.
9. Karki S, Chakrabarti P, Huang G,Wang H, Farmer SR, et al. (2011) The multi-level action of fatty acids on adiponectin production by fat cells. PloS one 6(11): e28146.
10. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nature clinical practice Endocrinology & metabolism 2009 5(3)150-159.
11. Wilcox G (2005) Insulin and insulin resistance. The Clinical biochemist Reviews/Australian Association of Clinical Biochemists 26(2): 19-39.
12. Hajer GR, van Haeften TW, Visseren FL (2008) Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. European heart journal 29(24): 2959-2971.
13. Qu D, Liu J, Lau CW, Huang Y (2014) Interleukin-6 in diabetes and cardiovascular complications. British journal of pharmacology.
14. Febbraio MA (2014) Role of interleukins in obesity: implications for metabolic disease. Trends in endocrinology and metabolism: TEM.
15. Pickup JC (2004) Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes care 27(3): 813-823.
16. Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, et al. (2003) Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 52(3): 812-817.
17. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE (2004) Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 53(3): 693-700.
18. Kolfschoten IG, Roggli E, Nesca V, Regazzi R (2009) Role and therapeutic potential of microRNAs in diabetes. Diabetes, obesity & metabolism 11 Suppl 4: 118-129.
19. McClelland AD, Kantharidis P (2014) microRNA in the development of diabetic complications. Clin Sci (Lond) 126(2): 95-110.
20. Balasubramanyam M, Aravind S, Gokulakrishnan K, Prabu P, Sathishkumar C, et al. (2011) Impaired miR-146a expression links subclinical inflammation and insulin resistance in Type 2 diabetes. Molecular and cellular biochemistry 351(1-2): 197-205.
21. Cui JG, Li YY, Zhao Y, Bhattacharjee S, Lukiw WJ (2010) Differential regulation of interleukin-1 receptor-associated kinase-1 (IRAK-1) and IRAK-2 by microRNA-146a and NF-kappaB in stressed human astroglial cells and in Alzheimer disease. The Journal of biological chemistry 285(50): 38951-38960.
22. Liu F, Zeng ZG, Ding CZ, Shao Q, Li Y, et al. (2010) [Expression of microRNA-146a in lipopolysaccharide challenged alveolar macrophages in vitro]. Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue 22(9): 540-542.
23. Nahid MA, Pauley KM, Satoh M, Chan EK (2009) miR-146a is critical for endotoxin-induced tolerance: IMPLICATION IN INNATE IMMUNITY. The Journal of biological chemistry 284(50): 34590-34599.
24. Taganov KD, Boldin MP, Chang KJ, Baltimore D (2006) NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proceedings of the National Academy of Sciences of the United States of America 103(33): 12481-12486.
25. Xu WD, Lu MM, Pan HF, Ye DQ (2012) Association of MicroRNA-146a with autoimmune diseases. Inflammation 35(4): 1525-1529.
26. Bi Y, Liu G, Yang R (2009) MicroRNAs: novel regulators during the immune response. Journal of cellular physiology 218(3): 467-472.
27. Donners MM, Wolfs IM, Stoger LJ, van der Vorst EP, Pottgens CC, et al. (2012) Hematopoietic miR155 deficiency enhances atherosclerosis and decreases plaque stability in hyperlipidemic mice. PloS one 7(4): e35877.
28. El-Ekiaby N, Hamdi N, Negm M, Ahmed R, Zekri AR, et al. (2012) Repressed induction of interferonrelated microRNAs miR-146a and miR-155 in peripheral blood mononuclear cells infected with HCV genotype 4. FEBS open bio 2: 179-186.
29. O'Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D (2007) MicroRNA-155 is induced during the macrophage inflammatory response. Proceedings of the National Academy of Sciences of the United States of America 104(5): 1604-1609.
30. O'Connell RM, Kahn D, Gibson WS, Round JL, Scholz RL, et al. (2010) MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity 33(4): 607-619.
31. Urbich C, Kuehbacher A, Dimmeler S (2008) Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovascular research 79(4): 581-588.
32. Corral-Fernandez NE, Salgado-Bustamante M, Martinez-Leija ME, Cortez-Espinosa N, Garcia- Hernandez MH, et al. (2013) Dysregulated miR-155 expression in peripheral blood mononuclear cells from patients with type 2 diabetes. Experimental and clinical endocrinology & diabetes: official journal, German Society of Endocrinology [and] German Diabetes Association 121(6): 347-353.
33. Grasedieck S, Scholer N, Bommer M, Niess JH, Tumani H, et al. (2012) Impact of serum storage conditions on microRNA stability. Leukemia 26(11): 2414-2416.
34. Cheng L, Sharples RA, Scicluna BJ, Hill AF (2014) Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood. Journal of extracellular vesicles 3.
35. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell research 18(10): 997-1006.
36. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, et al. (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences of the United States of America 105(30): 10513-10518.
37. Sethi P, Lukiw WJ (2009) Micro-RNA abundance and stability in human brain: specific alterations in Alzheimer's disease temporal lobe neocortex. Neuroscience letters 459(2): 100-104.
38. Kong L, Zhu J, Han W, Jiang X, Xu M, et al. (2011) Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study. Acta diabetologica 48(1): 61-69.
39. Diagnosis and classification of diabetes mellitus. (2011) Diabetes care, 34 Suppl 1: S62-69.
40. Boldin MP, Taganov KD, Rao DS, Yang L, Zhao JL, et al. (2011) miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. The Journal of experimental medicine 208(6): 1189-1201.
41. Perry MM, Moschos SA, Williams AE, Shepherd NJ, Larner-Svensson HM, et al. (2008) Rapid changes in microRNA-146a expression negatively regulate the IL-1beta-induced inflammatory response in human lung alveolar epithelial cells. J Immunol 180(8): 5689-5698.
42. Herder C, Baumert J, Thorand B, Martin S, Lowel H, et al. (2006) Chemokines and incident coronary heart disease: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Arteriosclerosis, thrombosis, and vascular biology 26(9): 2147-2152.
43. Costantini S, Capone F, Guerriero E, Marfella R, Sorice A, et al. (2012) Cytokinome profile of patients with type 2 diabetes and/or chronic hepatitis C infection. PloS one 7(6): e39486.
44. Freire WR, Ramirez MJ, Belmont P, Mendieta M, Silva K, et al. (2013) RESUMEN EJECUTIVO, TOMO I. Encuesta Nacional de Salud y Nutrición Ecuador. ENSANUT-ECU 2011-2013. In: Ministerio de Salud Pública/Instituto Nacional de Estadística y Censos Quito- Ecuador.
45. You WK, McDonald DM (2008) The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis. BMB reports 41(12): 833-839.
46. Saiki A, Watanabe F, Murano T, Miyashita Y, Shirai K (2006) Hepatocyte growth factor secreted by cultured adipocytes promotes tube formation of vascular endothelial cells in vitro. Int J Obes (Lond) 30(11): 1676-1684.
47. Schubert SY, Benarroch A, Ostvang J, Edelman ER (2008) Regulation of endothelial cell proliferation by primary monocytes. Arteriosclerosis, thrombosis, and vascular biology 28(1): 97-104.
48. Alvarez-Perez JC, Ernst S, Demirci C, Casinelli GP, Mellado-Gil JM, et al. (2014) Hepatocyte growth factor/c-Met signaling is required for beta-cell regeneration. Diabetes 63(1): 216-223.
49. Satani K, Konya H, Hamaguchi T, Umehara A, Katsuno T, et al. (2006) Clinical significance of circulating hepatocyte growth factor, a new risk marker of carotid atherosclerosis in patients with Type 2 diabetes. Diabetic medicine: a journal of the British Diabetic Association 23(6): 617-622.
50. Lee S, Lee HC, Kwon YW, Lee SE, Cho Y, et al. (2014) Adenylyl cyclase-associated protein 1 is a receptor for human resistin and mediates inflammatory actions of human monocytes. Cell metabolism 19(3): 484-497.
51. Nagaev I, Bokarewa M, Tarkowski A, Smith U (2006) Human resistin is a systemic immune-derived proinflammatory cytokine targeting both leukocytes and adipocytes. PloS one 1: e31.
52. Burnett MS, Lee CW, Kinnaird TD, Stabile E, Durrani S, et al. (2005) The potential role of resistin in atherogenesis. Atherosclerosis 182(2): 241-248.
53. Rashid S (2013) Mechanism by which Elevated Resistin Levels Accelerate Atherosclerotic Cardiovascular Disease. Rheumatol Curr Res 3(115).